IDEXX Laboratories Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 6/6
IDEXX Laboratories hat ein Gesamteigenkapital von $1.6B und eine Gesamtverschuldung von $873.9M, wodurch sich der Verschuldungsgrad auf 54% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $3.4B bzw. $1.7B. IDEXX Laboratories Das EBIT des Unternehmens beträgt $1.2B, so dass der Zinsdeckungsgrad 62.3 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $308.6M.
Wichtige Informationen
54.0%
Verhältnis von Schulden zu Eigenkapital
US$873.90m
Verschuldung
| Zinsdeckungsgrad | 62.3x |
| Bargeld | US$308.64m |
| Eigenkapital | US$1.62b |
| Gesamtverbindlichkeiten | US$1.73b |
| Gesamtvermögen | US$3.35b |
Jüngste Berichte zur Finanzlage
We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
Sep 18
IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet
Apr 11IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 15Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Sep 07These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
May 31Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly
Feb 22Recent updates
At US$420, Is It Time To Put IDEXX Laboratories, Inc. (NASDAQ:IDXX) On Your Watch List?
Nov 19IDEXX Laboratories Q3: Weak End-Market Demand Continues
Nov 11Investors Appear Satisfied With IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Prospects
Oct 28Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 15We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
Sep 18A Look At The Intrinsic Value Of IDEXX Laboratories, Inc. (NASDAQ:IDXX)
Sep 05What Is IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Doing?
Aug 20IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits
Aug 12A Look Into IDEXX Laboratories' (NASDAQ:IDXX) Impressive Returns On Capital
Jul 02Looking For Fast Growth In Healthcare? IDEXX Has You Covered
Jun 28Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jun 04Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?
May 21IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 03What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You
Apr 27IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet
Apr 11IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)
Apr 08Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jan 30IDEXX Laboratories: Valuation Rerating Doesn't Seem Justified
Jan 16Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jan 15IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit
Dec 31IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 15Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Oct 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 10Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Sep 07Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jul 04These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
May 31At US$484, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?
Apr 05Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly
Feb 22Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Jan 05Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Nov 24When Should You Buy IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Sep 20IDEXX Laboratories: Outstanding Business, But Valuation Is Key
Aug 15These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
Aug 15IDEXX Laboratories Stock Is Very Expensive
Aug 08IDEXX Laboratories Non-GAAP EPS of $1.58 misses by $0.05, revenue of $860.55M misses by $1.57M
Aug 02Are IDEXX Laboratories, Inc. (NASDAQ:IDXX) Investors Paying Above The Intrinsic Value?
Jul 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Might Deserve Your Attention Today
Jul 12Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jun 16IDEXX Laboratories: Great Business, But Still Overvalued
May 25Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: IDXXDie kurzfristigen Aktiva des Unternehmens ($1.4B) übersteigen seine kurzfristigen Passiva ($1.0B).
Langfristige Verbindlichkeiten: IDXXDie kurzfristigen Vermögenswerte des Unternehmens ($1.4B) übersteigen seine langfristigen Verbindlichkeiten ($723.5M).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: IDXXDie Nettoverschuldung im Verhältnis zum Eigenkapital (34.9%) wird als zufriedenstellend angesehen.
Schulden abbauen: IDXX Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 456.8% auf 54% zurückgegangen.
Schuldendeckung: IDXXDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (104.9%).
Zinsdeckung: IDXXDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (62.3x Coverage) gut gedeckt.